Amgen profit beats estimates, next MariTide studies start by mid-year
Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...
Amgen profits rise, next MariTide studies start by mid-year
Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...
FierceBiotech14h
Amgen's early-stage obesity asset slapped with FDA hold
Amgen’s mysterious obesity asset will remain a mystery for a bit longer—the FDA has put the candidate’s phase 1 trial ...
STAT14h
Study of Amgen’s early obesity candidate paused by FDA
The company said the agency's hold was "not related to the drug,” dubbed AMG 513, and that discussions were underway to ...
The Motley Fool: An inside look at Amgen’s fall
Shares of the company began plunging in November, but its overall strength should set the stock up for some serious potential ...
Amgen says Phase 1 AMG 513 obesity study placed on clinical hold by FDA
Amgen (AMGN) provided updates on selected product and pipeline programs, including that a Phase 1 study of AMG 513 in people living with ...
The Motley Fool: Not-so-bad cinical trial results
Shares of Amgen (Nasdaq: AMGN) started crashing in early November and didn’t improve when the company released data from a ...
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS
Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.
pharmaphorum5d
Amgen's big reveal of obesity data falls a little flat
Top-line phase 2 results with Amgen's MariTide drug for obesity are finally in – but the highly anticipated doesn't seem to have lived up to investor expectations. MariTide (maridebart ...
BioPharma Dive7d
Versant invests again in obesity, this time backing Helicore Biopharma
Helicore, which is developing a GIP-blocking antibody, is the fourth obesity drug developer to receive funding from Versant ...